Previous studies located T-cell recognition of the nucleocapsid of the hepatitis B virus (HBcAg) to residues 120-140 in mice bearing the H-2' or H-2" haplotypes. Herein, we demonstrate that B10.S (H-2') and B10 (H-2b) H-2 congenic strains recognize distinct T-cell sites within the p120-140 (a synthetic peptide corresponding to residues 120-140 of HBcAg) sequence defined by p120-131 and p129-140, respectively. Peptide p120-131 stimulates B1O.S HBcAg-primed T cells, and reciprocally p120-131-primed T cells recognize HBcAg. Similarly, the p129-140 sequence is a T-cell recognition site relevant to the native HBcAg in the B10 strain. It is also shown that these 12-residue peptides efficiently prime T-helper cells, which are capable of eliciting antibody production to HBcAg in vivo. These observations prompted us to examine the ability of the HBcAg-specific p120-140 sequence to function as a T-cell carrier moiety as a component of a totally synthetic hepatitis B vaccine. For this purpose a synthetic B-cell epitope from the pre-S(2) region (pl33-140) of the viral envelope was chosen because this sequence represents a dominant antibody-binding site of the envelope. Immunization of B1O.S and B10 strains with the synthetic composite peptide c120-140-(133-140) elicited anti-peptide antibody production, which was crossreactive with the native viral envelope. Furthermore, c120-140-(133-140) immunization primed p120-131-specific T cells in the B1O.S strain and p129-140-specific T cells in the B10 strain, which recognized HBcAg and provided T-helper cell function for anti-envelope antibody production in vivo. These results demonstrate the feasibility of constructing complex synthetic immunogens that represent multiple proteins of a pathogen and are capable of engaging both T and B cells relevant to the native antigens.
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The hepatitis B virus (HBV) consists of an outer envelope, composed of three coterminal polypeptides (P25, GP33, and P39), and an inner nucleocapsid, which encapsidates the viral genome. The nucleocapsid of the HBV is a 27-nm particle composed of multiple copies of a single polypeptide of Mr 21,000 (P21), and the intact structure exhibits hepatitis B core antigenicity (HBcAg) . A nonparticulate form of HBcAg, designated HBeAg, may be present in the serum during HBV infection. Although HBcAg and HBeAg are serologically distinct, the primary amino acid sequences show significant identity (serum HBeAg lacks the C-terminal 34 residues of HBcAg) (1) . The hepatitis B surface envelope (HBsAg) is composed of a major polypeptide (P25) (2) . The larger polypeptides [a glycoprotein of Mr 33,000 (GP33) and P39] share the 226 amino acids of P25 (S region) at the C terminus and possess additional residues at the N terminus. The pre-S(2) region consists of 55 residues N-terminal to the S region (3) , and the pre-S(1) region consists of 119 residues N-terminal to the pre-S(2) region (4).
Vaccination with envelope [S or pre-S(2)] or nucleocapsid antigens has been reported to protect against HBV infection (5-7). Because antibodies to HBcAg (anti-HBc antibodies) are not virus neutralizing, the mechanism of protection by HBcAg is unknown. However, an interrelationship between the immune responses to HBsAg and HBcAg has recently been reported. HBcAg-specific T cells are able to provide T-helper (Th)-cell activity for anti-S, anti-pre-S(2), and antipre-S(1)-specific antibody production if HBcAg and the envelope proteins are present within the same particle (i.e., the virion) (8) . This phenomenon may explain the mechanism of protection by HBcAg vaccination (8) .
Recently, we demonstrated that HBcAg functioned as a T-cell-independent antigen in athymic mice (9) and stimulated efficient T-cell activation in euthymic mice (9, 10) . Examination of the fine specificity of T-cell recognition of HBcAg revealed multiple T-cell sites within the HBcAg sequence, and the site recognized is dependent on the H-2 haplotype of the responding strain (10) . It is noteworthy that the H-2s and H-2b strains both recognize p120-140, a synthetic peptide corresponding to residues 120-140 of the HBcAg sequence. Herein, it is shown that the H-2S and H-2b strains actually recognize distinct T-cell sites within the p120-140 sequence. Additionally, the ability of defined synthetic T-cell sites to prime functional Th-cell activity and induce anti-HBc production in vivo is also demonstrated. These observations and the ability of HBcAg-specific Th cells to elicit anti-envelope antibody production (8) prompted us to examine the potential of p120-140 to act as a T-cell carrier moiety as a component of a prototypic, synthetic HBV vaccine. An eight-residue peptide previously shown to represent a dominant antibody-binding site within the pre-S(2) region of the envelope (11) tTo whom reprint requests should be addressed.
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and HBeAg, respectively) (1) supplied by M. Mayumi (Jichi Medical School, Tochigi-Ken, Japan). The peptides were synthesized by the Merrifield solid-phase method and were subjected to HPLC on a C18 reverse-phase column. All peptides used eluted as a single major peak (>90%). The structural polypeptide (P21) of the HBcAg particle consists of 183 amino acids. The following synthetic peptides were utilized for this study and are designated by amino acid position from the N terminus of HBcAg: p120-140, Val-SerPhe-Gly-Val-Trp-Ile-Arg-Thr-Pro-Pro-Ala-Tyr-Arg-Pro-ProAsn-Ala-Pro-Ile-Leu; p120-131, Val-Ser-Phe-Gly-Val-TrpIle-Arg-Thr-Pro-Pro-Ala; and p129-140, Pro-Pro-Ala-TyrArg-Pro-Pro-Asn-Ala-Pro-Ile-Leu. Additional peptides used were p133-140 [a pre-S(2) region peptide; N terminus designated as residue 120], Asp-Pro-Arg-Val-Arg-Gly-Leu-Tyr, and the composite peptide c120-140-(133-140) consisting of residues 120-140 of the HBcAg sequence and residues 133-140 of the pre-S(2) region sequence, which was produced in a single synthesis.
T data are expressed as cpm corrected for background proliferation in the absence of antigen (Acpm). All T-cellactivation experiments were performed at least twice, and representative experiments are depicted.
In Vivo Th-Ceil Assay. Th-cell activity was determined by the ability of peptide-primed mice to produce anti-HBc antibody in vivo after challenge with a suboptimal dose of HBcAg. Groups of five mice were primed i.p. with 100 ,ug of peptide in CFA. Control mice were primed with CFA alone. Three weeks after priming, the mice were challenged with 0.1 ,g of HBcAg in incomplete Freund's adjuvant or adjuvant alone, and sera were collected for measurement of anti-HBc IgG 7 days after challenge.
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Measurement of in Vivo Antibody Production. Pooled murine sera were evaluated for antibody in an indirect, solidphase RIA using solid-phase HBcAg (0.1 ,g per well), HBsAg/GP33 (0.1 ,g per well), or synthetic peptides (1 ug per well) and goat anti-mouse IgG as second antibody. Antibodies were quantitated with an 125I-labeled, affinitypurified swine anti-goat immunoglobulin as described (14) . Recombinant HBsAg particles containing approximately 35% GP33 (15) 
S (H-2S) HBcAg-primed T cells proliferated in response to
HBcAg, the complete peptide (p120-140), and p120-131 but not p129-140. p125-136 was also active, but it was 500-fold less efficient as compared to p120-131 (data not shown). Note that the dose-response curves for HBcAg-primed T cells stimulated with HBcAg or the active peptides were similar. The reciprocal experiments involved priming with peptides and challenging in vitro with HBcAg or peptides. BlO.S p120-140-primed T cells recognized HBcAg, the immunizing peptide (p120-140), and p120-131, but not p129-140 (Fig. lb) . Therefore, similar to T cells primed with native HBcAg, p120-140-primed BlO.S T cells recognized p120-131. BlO .S T cells primed with p120-131 were activated by p120-140, p120-131, and HBcAg (Fig. ic) . Therefore, the 12-residue peptide p120-131 was sufficiently immunogenic to prime HBcAg-specific T cells in vivo. p129-140 was only marginally immunogenic in the BlO.S strain (Fig.  ld) . Similar experiments were performed in H-2 congenic B10
(H-2b) mice (Fig. 2) . BlO HBcAg-primed T cells proliferated in response to HBcAg, p120-140, and p129-140 but not to Ag, HBeAg, p120-140, p120-131, p129-141, or media alone, and T-cell proliferation was determined as described in Fig. 1. p120-131 or p125-136 (Fig. 2a) , in contrast to B1O.S HBcAg-primed T cells. Because the p120-140 sequence is common to both HBcAg and HBeAg, these results predict that HBcAg and HBeAg are crossreactive at the level of T-cell proliferation in the B1O.S and B10 strains. The availability of recombinant HBeAg allowed us to confirm this prediction because B10 HBcAg-primed T cells recognized HBeAg (Fig.  2a) . B10 p120-140-or p129-140-primed T cells were specific for p129-140 and recognized HBcAg approximately as well as the immunizing peptide ( Fig. 2 b and d) . p129-140-primed T cells also proliferated in response to HBeAg (Fig. 2d) . p120-131 was nonimmunogenic in the B10 strain (Fig. 2c) . Identical experiments performed in B1O.BR (H-2k) mice revealed that, although B1O.BR HBcAg-primed T cells recognized HBcAg and HBeAg, the p120-140 sequence and the truncated peptides were neither stimulatory nor immunogenic (data not shown).
Synthetic Peptides p120-140, p120-131, and p129-140
Can Prime Functional Th-Cell Activity in Vivo. As an alternative method of examining the fine specificity of T-cell recognition of HBcAg and as a means of determining the functional ability of synthetic T-cell sites to prime antibody production in vivo, Th-cell assays were performed. Priming with synthetic T-cell sites, p120-140, p120-131, and p129-140, did not elicit anti-HBc antibody production in B1O.S mice, and p129-140 induced only minimal anti-HBc in B10 mice (Fig. 3) . Therefore, although these peptides contain T-cell recognition sites, the B-cell epitopes present on the peptides are not relevant to or are not exposed on the native HBcAg (i.e., peptide-specific). Therefore, it was possible to examine the ability of these peptides to prime Th cells in vivo directly as opposed to performing T-cell transfer experiments. This approach requires that the memory Th cells primed by immunization with peptide be recalled by challenge with HBcAg, indicating the relevance of the synthetic T-cell recognition site to the native molecule. In the B1O.S strain, unprimed mice challenged with HBcAg produced minimal anti-HBc antibodies (1:40) in vivo, whereas p120-140-primed mice challenged with HBcAg produced anti-HBc IgG efficiently (1:5120) 7 days after the challenge (Fig. 3 Upper) . To examine the fine specificity of the Th-cell activity, B1O.S mice were primed with p120-131 or p129-140 and then challenged with HBcAg. Priming with p120-131 elicited significant anti-HBc production (256 times the unprimed value), and p129-140 was only marginally reactive (4 times the unprimed value) (Fig. 3) . Similarly, immunization with p120-140 primed anti-HBc production in the B10 strain (1:10,240). However, in contrast to the B1O.S strain, p129-140 primed anti-HBc production in the B10 strain, and p120-131 was inactive (Fig. 3 shown to encompass distinct Th-cell recognition sites for B1O.S and B10 mice capable of inducing anti-HBc production in vivo, it was of interest to determine whether p120-140 coupled directly to a synthetic B-cell epitope could act as a T-cell carrier for that epitope. The B-cell epitope chosen was the pre-S(2) region peptide p133-140, which was previously shown to represent a dominant antibody-binding site within the pre-S(2) region of HBsAg/GP33 particles (11) . The unconjugated p133-140 sequence of the pre-S(2) region is nonimmunogenic in the BlO.S, B10, and B1O.BR strains (data not shown). After primary immunization with c120-140-(133-140), the B1O.S strain produced antibody to the HBcAg-specific peptide (p120-140), which did not crossreact with native HBcAg (i.e., was peptide-specific), and antibody to the pre-S(2) region peptide (p133-140), which did crossreact with native HBsAg/GP33 particles ( Table 1) . After the secondary immunization, antibody titers increased 4-fold (anti-p120-140) and 16-fold (anti-p133-140). Note that the secondary anti-p120-140 antibody was only minimally reactive with the native HBcAg protein, whereas the antip133-140 antibody was highly crossreactive with the native HBsAg/GP33 protein. The B10 strain was less responsive to c120-140-(133-140) immunization than the B1O.S strain, as evidenced by the necessity for a booster immunization to elicit anti-p133-140 antibody production, which was 4 to 8 times less as compared to the secondary response of the B1O.S strain (Table 1 ). Similar to the B1O.S strain, the BlO anti-p133-140 antibody was highly crossreactive with native HBsAg/GP33, whereas anti-p120-140 was only minimally crossreactive with native HBcAg. Both the B1O.S and B10 strains produced high-titered, predominantly peptidespecific antibody to the p120-140 sequence. In both strains, the antibody was specific for p129-140 (data not shown).
Predictably from the T-cell proliferation and Th-cell experiments, the B1O.BR strain was a nonresponder to immunization with c120-140-(133-140). These results indicate that the HBcAg-specific synthetic peptide p120-140 can function as a T-cell carrier for a synthetic B-cell epitope represented on the envelope of the HBV in strains that recognize the p120-140 sequence of HBcAg at the T-cell level. Fine Specificity of T-Cell Recognition of the Synthetic Immunogen c120-140-(133-140). In order to confirm that the predicted sites within the composite immunogen were functioning as T-cell recognition sites, c120-140-(133-140)- immunized mice were evaluated at the T-cell level. B1O.S c120-140-(133-140)-primed T cells responded to pl20-140, p120-131, and to native HBcAg. The B-cell epitope (p133-140) and native HBsAg/GP33 particles were nonstimulatory at all concentrations (Fig. 4 Top). B10 c120-140-(133-140)-primed T cells were activated by p120-140, p129-140, and native HBcAg. The B-cell epitope (p133-140) and native HBsAg/GP33 were nonstimulatory at all concentrations (Fig. 4 Middle). The significantly higher peptidespecific T-cell proliferative responses of the B1O.S strain as compared to the B10 strain may explain the greater anti-pre-S(2) antibody production observed in the B1O.S strain after c120-140-(133-140) immunization (Table 1) . B1O.BR c120-140-(133-140)-primed T cells were nonresponsive to the entire antigen panel (Fig. 4 Bottom) . These results and the antibody results depicted in Table 1 indicate that T-cell recognition of the composite peptide is H-2-dependent and correlates with the specificity patterns observed for free p120-140 in terms of 
